USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: ZACHARON PHARMACEUTICALS, INC.
City: San Diego
State: CA
Zip+4: 92121-
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,913,609.00 8
SBIR Phase II $4,454,452.00 2

Award List:

Development of a cell-based screen for inhibitors of ganglioside biosynthesis

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Brett E. Crawford
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): The underlying hypothesis of this proposal is that inhibitors of ganglioside biosynthesis will prevent or slow the growth of neural crest-derived tumors (neuroblastoma, melanoma, astrocytoma). These tumor types produce an altered array of gangliosides that… More

Chondroitin Sulfate Inhibitor Screen for Neural-Regeneration Drugs

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Charles A. Glass
Award Amount: $114,868.00
Abstract:
DESCRIPTION (provided by applicant): In accordance with the National Institute of Neurological Disorders and Stroke (NINDS) priorities, the goal of this proposal is to develop a system to discover drugs that have the potential to reduce scarring after spinal cord injury. In the United States,… More

Inhibitors of Heparan Sulfate Biosynthesis and Cancer

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Charles A. Glass
Award Amount: $196,245.00
Abstract:
DESCRIPTION (provided by applicant): The underlying hypothesis of this proposal is that inhibitors of heparan sulfate biosynthesis will slow tumor growth. Genetic and pharmacological data has validated heparan sulfate as a novel anti-cancer target. This proposal describes a drug discovery program… More

Structure-activity relationship study of an inhibitor of tumor metastasis

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $188,112.00
Abstract:
DESCRIPTION (provided by applicant): A large number of deaths from epithelial tumors of the breast, prostate, lung, ovary, liver, and kidney are caused by metastatic spread of the primary tumor. Unfortunately, there are currently no drugs on the market tha t directly target cancer cells in the… More

Development of Novel Inhibitors of Ganglioside Biosynthesis

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $1,455,563.00
Abstract:
DESCRIPTION (provided by applicant): The underlying hypothesis of this proposal is that inhibitors of ganglioside biosynthesis will prevent or slow the growth of neural crest-derived tumors (neuroblastoma, melanoma, and astrocytoma). Clinical studies have shown that these tumor types consistently… More

Substrate Optimization Therapy: A Novel Therapy for Mucopolysaccharidosis

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Brett E. Crawford
Award Amount: $339,513.00
Abstract:
DESCRIPTION (provided by applicant): Project Summary The studies proposed in this application will test the feasibility of treating mucopolysaccharidosis (MPS) through a novel therapeutic approach called Substrate Optimization Therapy (SOT). MPS is a family of lysosomal storage diseases… More

A Novel Small Molecule Therapy for Tay-Sachs and Sandhoff Diseases

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Brett E. Crawford – 858-754-3031
Award Amount: $342,896.00
Abstract:
DESCRIPTION (provided by applicant): Project Summary Using a novel high-throughput screening approach, we have recently identified the first selective small molecule inhibitors of the biosynthesis of gangliosides. The proposed funding will enable important preclinical development activities… More

Substrate Optimization Therapy: A Novel Therapy for Mucopolysaccharidosis

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Brett E. Crawford – 858-754-3031
Award Amount: $2,998,889.00
Abstract:
DESCRIPTION (provided by applicant): Project Summary The studies proposed in this application are aimed at progressing an innovative approach to treating mucopolysaccharidoses (MPS) toward clinical trials. MPS is a family of lysosomal storage diseases caused by mutations in the enzymes that… More

Development of a Novel Biomarker for Mucopolysaccharidosis I, II, and VI

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Brett E. Crawford – 858-754-3031
Award Amount: $335,739.00
Abstract:
DESCRIPTION (provided by applicant): The goal of this proposal is to develop a biomarker capable of definitively diagnosing and monitoring response to therapy in patients with Mucopolysaccharidosis (MPS) I, II and VI. These diseases are rare genetic conditions each caused by unique deficiencies in… More

Development of a Small Molecule Therapy for Metachromatic Leukodystrophy

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Brett E. Crawford – 858-754-3031
Award Amount: $296,236.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this Phase I SBIR proposal is to develop a central nervous system penetrant (CNS) small molecule therapy for Metachromatic Leukodystrophy (MLD). We will accomplish this by developing a cellular model ofMLD to screen compound libraries in order to… More